The Lack of Systemic and Subclinical Side Effects of Botulinum Neurotoxin Type-A in Patients Affected by Post-Stroke Spasticity: A Longitudinal Cohort Study

Marco Battaglia 1,2,*, Margherita Beatrice Borg 1,2,*, Lara Torgano 1,2,°, Alberto Loro 1,2,°, Lucia Cosenza 3, Michele Bertoni 4, Alessandro Picelli 5,6,°, Andrea Santamato 7,°, Marco Invernizzi 1,8,°, Francesca Uberti 9,°, Claudio Molinari 10, Stefano Carda 11 and Alessio Baricich 1,2,°

Abstract: Botulinum Neurotoxin type-A (BoNT-A) is the treatment of choice for focal post-stroke spasticity (PSS). Due to its mechanism of action and the administration method, some authors raised concern about its possible systemic diffusion leading to contralateral muscle weakness and autonomic nervous system (ANS) alterations. Stroke itself is a cause of motor disability and ANS impairment; therefore, it is mandatory to prevent any source of additional loss of strength and adjunctive ANS disturbance. We enrolled 15 hemiparetic stroke survivors affected by PSS already addressed to BoNT-A treatment. Contralateral handgrip strength and ANS parameters, such as heart rate variability, impedance cardiography values, and respiratory sinus arrhythmia, were measured 24 h before (T0) and 10 days after (T1) the ultrasound (US)-guided BoNT-A injection. At T1, neither strength loss nor modification of the basal ANS patterns were found. These findings support recent literature about the safety profile of BoNT-A, endorsing the importance of the US guide for a precise targeting and the sparing of “critical” structures as vessels and nerves.

Keywords: muscle spasticity; botulinum toxin; heart rate; stroke; autonomic nervous system; rehabilitation

Key Contribution: Support the already known high safety profile of BoNT-A, giving further evidence about the non-significant adverse effects on muscle strength and autonomic nervous system activity due to its uncommon systemic diffusion.
1. Introduction

Li and colleagues recently re-defined spasticity as “velocity- and muscle length-dependent increase in resistance to externally imposed muscle stretch. It results from hyperexcitable descending excitatory brainstem pathways and from the resultant exaggerated stretch reflex responses” [1]. Spasticity is among the most severe clinical expressions of the upper motor neuron syndrome (UMNS), and stroke represents one of the major causes of UMNS, with a global incidence of approximately 258/10,000/year [2]. In Europe, 1.1 million people suffer from a stroke each year [3], and it represents the fifth-leading death cause and the leading long-term disability cause in the US [4].

PSS more frequently affects the upper limb than the lower limb, with an incidence that varies from 7 to 38% in the upper limb during the first 12 months after the acute event [5,6].

Alongside with PSS, several signs and symptoms characterize stroke survivors in the subacute and chronic phase. Among these, pain, fatigue, paresis, sensorimotor impairment, depression, and cognitive dysfunction mostly contribute to an impaired quality of life (QoL) [7,8].

Regarding fatigue, it was described by Staub et al. as “a feeling of early exhaustion with weariness, lack of energy and aversion to effort that develops during physical or mental activity and is usually not ameliorated by rest” [9]. The prevalence of fatigue in stroke survivors ranges between 30 and 77%, and, alongside depression [10], it negatively affects both physical and psychological rehabilitation programs, leading to a significantly increased chance of relapsing neurovascular events. Furthermore, increasing the risk of cardiovascular complications, it is an important death predictor after stroke onset [11,12]. To this end, it is crucial to finely tailor the rehabilitation program to prevent and contain fatigue expression.

Notably, PSS affects all the three domains of the International Classification of Functioning, Disability and Health (ICF) of the World Health Organization (WHO) [13], resulting in reduced overall function; hence, lower levels of independence. Therefore, PSS treatment is a fundamental element in the multimodal management of hemiparetic stroke survivors.

The clinical management of PSS relies on an accurate physical examination and assessment of the spasticity grade, measured with the Modified Ashworth Scale (MAS) [14,15] or the Tardieu scale [16]. The treatment of choice consists in the intramuscular injection of Botulinum Neurotoxin type-A (BoNT-A), in close association with several non-pharmacological and/or surgical interventions [17–22].

BoNT-A already proved to be an effective and safe treatment for focal spasticity, providing a transient chemodenervation of injected muscles throughout the inhibition of the pre-synaptic release of acetylcholine at the neuromuscular junctions [23]. Together with its high efficacy and optimum safety profile [24], BoNT-A is specifically proved to be effective in reducing pain, improving mobility, walking ability, activities of daily living, and quality of life [25,26]. Therefore, BoNT-A is currently considered the gold standard treatment in patients affected by focal PSS.

Needless to say, it is crucial to assess the possibility of BoNT-A-induced local and general adverse reactions which have been reported in the scientific literature [27,28]. Systemic BoNT-A spread can be due to a combination of vascular and neural diffusion, leading to potential clinically relevant conditions. BoNT-A diffusion, spread, and migration [29] might lead to contralateral muscle weakness, dysphagia, dysarthria, and several autonomic nervous system (ANS) subclinical impairments, such as dry mouth; postural hypotension with consequent falls; constipation; and, particularly, cardiorespiratory drive alterations [30,31]. These incidental events, in fact, may seriously worsen already severely compromised patients affected by underlying weakness, fatigue, and stroke-induced ANS imbalance [32].

Commonly, validated tools are used to evaluate these potential alterations. For segmentary strength, the most feasible technique is the handgrip strength test [33]. Regarding ANS, a multiparametric approach is preferred, taking into consideration the heart rate variability (HRV) oscillations [34,35], the impedance cardiography (ICG) panel [36], and the
respiratory sinus arrhythmia (RSA) variations [37]. These values can be obtained through specific electrocardiographic (ECG) registrations.

Currently, these side effects have been only investigated on small populations, mainly in relation to high-dose administration, giving nonetheless promising results and so far confirming the high safety profile of BoNT-A [38,39]. Throughout the inclusion of subjects treated with lower doses of BoNT-A and considering the three main formulations (Incobotulinumtoxin A, Abobotulinumtoxin A, and Onabotulinumtoxin A), this study aims to investigate an additional population with a larger sample size.

The aim of this study is to assess whether BoNT-A treatment is associated with systemic side effects, such as contralateral weakness, or subclinical ANS alterations, as a consequence of systemic diffusion of the locally intramuscular-injected BoNT-A in hemiplegic stroke survivors affected by PSS.

2. Results

Seventy-five patients were pre-screened in order to participate in the study; 23 patients respected the inclusion and exclusion criteria. After losing eight patients at the follow-up, 15 subjects completed the study. All the patients were treated with BoNT-A, using one of the three commercialized drugs in Italy, as shown in Table 1.

Table 1. Demographic characteristics and pharmacological treatment distribution.

| Variable                  | N = 15 |
|---------------------------|--------|
| **Sex**                   |        |
| Male (%)                  | 9 (60%)|
| Female (%)                | 6 (40%)|
| **Hemiparetic side**      |        |
| Right                     | 6 (40%)|
| Left                      | 9 (60%)|
| **Etiology**              |        |
| Ischemic                  | 11 (73.3%)|
| Hemorragic                | 4 (26.7%)|
| **Mean age (SD)**         | 60.3 years old (13.6) |
| **Mean time from stroke (SD)** | 5.6 years (4.2) |
| **Molecule**              |        |
| Incobotulinumtoxin A (n)  | 2      |
| Abobotulinumtoxin A (n)   | 2      |
| Onabotulinumtoxin A (n)   | 11     |

The dose chosen for every injection site for each patient is reported in Table 2. In nine patients, muscles in both the upper and the lower limb were treated; in four patients, only in the upper limb; and in two, only in the lower limb.

The results of the handgrip strength test and the electrocardiographic registration of HRV, ICG, and RSA parameters showed no statistical differences between T0 and T1 after BoNT-A injections, as fully described in Table 3.

Subgroup analysis was implemented in order to compare higher-dose (700–800 UI of Onabotulinumtoxin A or 1500 UI of Abobotulinumtoxin A) with lower-dose subjects (other doses). No significant difference of parameter variations from T0 to T1 was found between the two groups, as seen in Table 4.
Table 2. Botulinum Neurotoxin type-A distribution per patient (ID number 1–15), per injection site. LD: latissimus dorsi; SS: subscapularis; PM: pectoralis major; BB: biceps brachii; B: brachialis; BR: brachioradialis; PT: pronator teres; FCU: flexor carpi ulnaris; FCR: flexor carpi radialis; FDS: flexor digitorum superficialis; FPL: flexor pollicis longus; FPB: flexor pollicis brevis; PL: palmaris longus; RF: rectus femoris; MG: medial gastrocnemius; LG: lateral gastrocnemius; SOL: soleus; TA: tibialis anterior; TP: tibialis posterior; FDL: flexor digitorum longus; FHL: flexor hallucis longus. All doses are in International Units (IU). I: IncobotulinumtoxinA; A: AbobotulinumtoxinA; O: OnabotulinumtoxinA.

| Muscle | ID   | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  | 13  | 14  | 15  |
|--------|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| LD     | 50   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| SS     | 50   | 50  |     |     |     |     |     |     |     |     |     |     |     |     |     |
| PM     | 60   | 60  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  |
| BB     | 30   | 30  | 30  | 20  |     |     |     |     |     |     |     |     |     |     |     |
| B      | 30   | 30  | 30  | 20  |     |     |     |     |     |     |     |     |     |     |     |
| BR     | 25   | 25  | 25  | 25  | 25  | 25  | 25  | 25  | 25  | 25  | 25  | 25  | 25  | 25  | 25  |
| PT     | 25   | 25  | 25  | 25  | 25  | 25  | 25  | 25  | 25  | 25  | 25  | 25  | 25  | 25  | 25  |
| FCIU   | 20   | 20  | 20  | 20  | 20  | 20  | 20  | 20  | 20  | 20  | 20  | 20  | 20  | 20  | 20  |
| FCR    | 50   | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  |
| FDS    | 50   | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  |
| FDP    | 50   | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  |
| FPL    | 50   | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  | 50  |
| FPB    | 50   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| PL     | 50   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Total  |     | 800 | 600 | 200 | 200 | 600 | 800 | 700 | 300 | 300 | 300 | 500 | 500 | 500 | 400 |

Table 3. Variations of the handgrip strength test and cardiorespiratory parameters from basal. No statistically significative modifications were found after BoNT-A treatment. SD: standard deviation; HRV: heart rate variability; ICG: impedance cardiography; IBIs: interbeat intervals; SDNN: standard deviation of normal-to-normal intervals; HR SD: heart rate standard deviation; RMSSD: root mean square of successive R-R intervals differences; LF: low frequency; HF: high frequency; LF/HF: ratio of LF-to-HF power; PEP: pre-ejection period; dz/dt min position: position of the minimum value of thoracic impedance; dz/dt min value: minimum value of thoracic impedance; RSA: respiratory sinus arrhythmia; RSA-0: the point where the RSA value is 0. Significance level: $p < 0.05$.

| Muscle | T0               | T1               | $p$-Value |
|--------|------------------|------------------|-----------|
|        | Mean (SD)        | Mean (SD)        |           |
| Handgrip [kg] | 24.48 (10.47)   | 24.49 (9.93)    | 0.97      |
| HRV    |                  |                  |           |
| IBIs number | 1494.33 (267.90) | 1580.07 (410.51) | 0.15      |
| IBIs average | 831.47 (123.11)  | 805.70 (161.36)  | 0.23      |
| SDNN   | 37.76 (15.49)    | 35.26 (19.86)    | 0.39      |
| HR SD  | 3.20 (0.97)      | 3.41 (1.54)      | 0.45      |
| RMSSD  | 23.16 (24.13)    | 19.78 (22.04)    | 0.25      |
| LF     | 317.02 (345.35)  | 300.80 (352.07)  | 0.19      |
| HF     | 86.58 (60.38)    | 173.20 (416.24)  | 0.36      |
| LF/HF  | 4.50 (3.63)      | 4.02 (3.22)      | 0.72      |
Table 3. Cont.

|                  | T0 Mean (SD) | T1 Mean (SD) | p-Value |
|------------------|--------------|--------------|---------|
| ICG              |              |              |         |
| PEP              | 103.07 (24.30) | 103.87 (23.97) | 0.99    |
| dz/dt min position | 120.67 (25.55) | 120.40 (28.88) | 0.66    |
| dz/dt min value  | −0.66 (0.27)  | −0.49 (0.33)  | 0.76    |
| Respiration      |              |              |         |
| RSA              | 28.00 (13.46) | 29.51 (20.22) | 0.49    |
| RSA-0            | 22.71 (9.89)  | 23.68 (17.08) | 0.50    |

Table 4. Comparison between high-dose and low-dose subgroups, from T0 to T1, in every considered parameter. SD: standard deviation; HRV: heart rate variability; ICG: impedance cardiography; IBIs: interbeat intervals; SDNN: standard deviation of normal-to-normal intervals; HR SD: heart rate standard deviation; RMSSD: root mean square of successive R-R intervals differences; LF: low frequency; HF: high frequency; LF/HF: ratio of LF-to-HF power; PEP: pre-ejection period; dz/dt min position: position of the minimum value of thoracic impedance; dz/dt min value: minimum value of thoracic impedance; RSA: respiratory sinus arrhythmia; RSA-0: the point where the RSA value is 0. Since the distribution was not normal, a Mann–Whitney test was performed. Significance level: p < 0.05.

|                  | N 4     | N 11    | p-Value |
|------------------|---------|---------|---------|
| Handgrip [kg]    | −0.02 (0.14) | 0.07 (0.13) | 0.94    |
| HRV              |         |         |         |
| IBIs number      | 0.04 (0.08)  | 0.05 (0.14) | 0.73    |
| IBIs average     | −0.03 (0.08) | −0.01 (0.11) | 0.62    |
| SDNN             | −0.29 (0.36) | 0.06 (0.42)  | 0.94    |
| HR SD            | −0.15 (0.38) | 0.15 (0.38)  | 0.98    |
| RMSSD            | −0.41 (0.37) | 0.29 (1.26)  | 0.83    |
| LF               | −0.37 (0.52) | 0.30 (1.40)  | 0.90    |
| HF               | −0.41 (0.37) | 1.70 (5.23)  | 0.69    |
| LF/HF            | −0.12 (0.36) | 0.06 (0.58)  | 0.76    |
| ICG              |         |         |         |
| PEP              | −0.05 (0.13) | 0.12 (0.50)  | 0.63    |
| dz/dt min position | −0.05 (0.24) | 0.04 (0.29)  | 0.98    |
| dz/dt min value  | −0.21 (0.38) | −0.23 (0.44) | 0.73    |
| Respiration      |         |         |         |
| RSA              | −0.05 (0.29) | 0.19 (0.90)  | 0.83    |
| RSA-0            | −0.04 (0.32) | 0.20 (0.97)  | 0.83    |

3. Discussion

Our results show no significative differences in every investigated variable before and after BoNT-A injections. Specifically, no variations of contralateral handgrip strength were found. Similarly, HRV, pre-ejection period (PEP), dz/dt min position, dz/dt min value, and respiratory sinus arrhythmia (RSA) parameters showed no discrepancies after BoNT-A treatment.

Additionally, the subgroup analysis confirmed the absence of a significant alteration of the variables from T0 to T1 between high- and low-dose patients, endorsing the hypothesis of the non-significant systemic side effects of BoNT-A, even with maximum dosages.

However, the nature of BoNT-A as a bacterial toxin and its intramuscular way of administration through multiple injections raised concerns about its possible systemic
diffusion and adverse effects. An internal spread has already been described inside the injected muscle, together with its diffusivity in adjacent muscular masses, trespassing aponeurosis, and also to the contralateral muscles [40,41]. However, to date, neither the entity nor the mechanism of botulinum toxin diffusion outside the injection site are well known. Various pathways have been hypothesized, including systemic spread, vascular diffusion, and retrograde axonal spread [30,41].

The potential systemic and subclinical adverse effects of BoNT-A treatment represent a crucial issue that requires deep investigations given the increasing trend of BoNT-A employment, thus representing a hot topic in rehabilitation.

In the scientific literature, there is not a univocal point of view. In more detail, in 2012, Thomas and colleagues described in two stroke survivors affected by spastic hemiparesis, previously inoculated with BoNT-A at the upper limb, the onset of contralateral weakness. After electromyographic examination, the presence of a neuro-muscular blockade in the non-treated contralateral limb muscles was revealed. Successively, weakness spontaneously recovered in few months [42]. Another more recent report published in 2020 concerned a patient who, after BoNT-A injections, showed paresis affecting the contralateral deltoid muscle. Even in this case, the neuromuscular blockade was proved through an electromyographic investigation, and the recovery was complete after 8 months. In this case, it is quite interesting that the contralateral paresis developed after the therapeutic switch from incobotulinum to abobotulinum toxin. Thus, the authors suggested extreme caution when converting from one molecule to another [30]. Luckily, these adverse events are uncommon and, indeed, in our larger study sample, we did not detect a variation of contralateral upper limb strength after BoNT-A effect onset.

Given the highly complex disability condition of stroke survivors needing a focal spasticity treatment, it is crucial to prevent any possible strength loss in the healthy limbs. Moreover, taking into consideration the frequency of post-stroke fatigue and its poor prognostic meaning [9–12], it is mandatory to avoid any source of possible treatment-induced weakness that could further severely worsen an already debilitated subject. Therefore, it is of primary importance to determine whether BoNT-A treatment could provoke contralateral weakness and/or paresis in bigger study samples, considering that this side effect may negatively impact the rehabilitation programs, the activities of daily living, and, consequently, the QoL of these patients. To this end, our results are promising, supporting BoNT-A safety.

Considering the ANS evaluation, HRV already represents a reliable marker which predicts the recurrence of stroke and cardiovascular accidents, post-stroke complications, and functional outcomes [34]. HRV is a physiological phenomenon finely regulated by several agents: at first, the sympathetic and parasympathetic balance; then, the respiration rate and depth, the baroreceptors reflex, and the rhythmic changes in vascular tone [35]. The combination of these mechanisms generates a constant oscillation typical of a healthy organism. Recent literature discusses how the neurological lesions after stroke can impoverish these physiological oscillations, and represent a major cause of ANS dysfunction, frequently leading to cardiovascular drive alterations [32]. Therefore, the role of BoNT-A in potentially negatively affecting this already altered condition needs to be clarified.

In fact, BoNT-A, due to its mechanism of action, may affect the parasympathetic nervous system and, thus, it also may impact cardiac regulation. The inhibition of the presynaptic release of acetylcholine could prevent the activation of M2 muscarinic receptors localized in the cardiac muscle, which are in charge of the vagal inhibition transmission. As reported by Girlanda et al., BoNT-A could then be responsible for subclinical changes in heart rate [43], which can be detected through HRV analysis.

HRV is described by time domains that quantify the variability of the interbeat intervals (IBIs), and frequency domains. Time domains include: IBIs number, IBIs average, standard deviation of normal-to-normal intervals (SDNN), heart rate standard deviation (HR SD), and root mean square of successive R-R intervals differences (RMSSD) [35]. Frequency domains, though, are calculated by a spectrum analysis based on the Fourier
transform, and are used to estimate the amount of absolute or relative signal energy found in different frequency bands. Spectrum components are classified in ultra-low-frequency (ULF), very-low-frequency (VLF), low-frequency (LF), and high-frequency (HF) bands. In our paper, we investigated only LF and HF because low-frequency (0.04–0.15 Hz) bundles mainly depend on the sympathetic nervous system and baroreceptor action, whereas the high-frequency (0.15–0.4 Hz) component is mostly under vagal control, indicating parasympathetic activity. Therefore, the ratio LF/HF expresses the balance between the sympathetic and parasympathetic nervous system on heart rate frequency variations [35].

Our results show no alteration of the autonomic drive after BoNT-A injection, in both time and frequency domains. Reviewing the current scientific literature, concordant findings are reported by Baricich et al. and Invernizzi et al. regarding the impact of high doses of IncobotulinumtoxinA and OnabotulinumtoxinA. In both cases, no differences of HRV subsequent to BoNT-A injections were found, even with total doses over 600 IU [38,39], supporting the thesis that focal spasticity treatment with botulinum toxin does not seem to affect the ANS activity.

In addition to the ECG traces, VU-AMS equipment allows the recording of ICG waves, obtained and analyzed through the software, VU-DAMS version 4.0. Specifically, the ICG parameters considered are the pre-ejection period (PEP), the dZ/dt min position, and the dZ/dt min value [36]. PEP reflects the left ventricular contractility representing the duration of the electric or isovolumic systole, and it is commonly used as a marker of sympathetic nervous system activation. The dZ/dt min position and volume parameters, representing, respectively, the minimum value of cardiac and thoracic impedance, give an indirect measure of left ventricle stroke volume.

These parameters measure the ANS influence on the cardiac muscle, and they are, therefore, a feasible tool to assess possible variations of contractility after BoNT-A inoculation.

Even in this case, no post-injection alteration was recorded in our population.

Finally, RSA is a further indirect index of vagal activity on heart rate. As inspiration is responsible for the cyclic suppression of the vagal tone, during this respiratory phase, it is physiological to observe a cardiac frequency increase [37]. Therefore, RSA and RSA-0 (which is the point where RSA value is 0) identify the balance between cardiac and respiratory function. RSA plays a major role in timing alveolar ventilation and perfusion. Reducing the heart rate during expiration is a form of energy-saving procedure, since it suppresses unnecessary heartbeats and, consequently, pulmonary blood flow, whereas the alveoli are in a low air volume condition.

Taking into consideration our study sample, characterized by a chronic disability and energy consumption imbalance, it is a primary issue to maintain the natural variability of the cardiopulmonary system under the influence of ANS as physiologically as possible. Even in this case, our results support the preservation of the physiological fluctuation of RSA after BoNT-A injection.

In conclusion, we suggest that there are no considerable influences of the locally injected botulinum toxin on the ANS activity. Therefore, we can assume that the treatment of focal post-stroke spasticity with BoNT-A does not seem to imply notable subclinical signs or symptoms of systemic diffusion in our population, even considering high doses that are frequently required to reach an adequate therapeutic effect.

The authors finally suggest the use of the US guide to perform BoNT-A injections. Given the potential vascular and axonal spread and the possible trans-aponeurosis diffusion [29], it should be common practice to perform the injection under a real-time US guide in order to obtain a precise targeting [44] and keep a safe distance from vascular, neural, and fascial structures.

The authors are aware of the limitations of this study.

Firstly, the study sample is quite small, even though the current literature is based on even smaller groups. Regardless, it could be difficult to generalize our results to the entire stroke survivor population.
Secondly, the panel of ANS parameters we considered is wide, but not complete. It is advisable to take into account other variables, such as the continuous recording of blood pressure and peripheral oxygen saturation. Regardless, the current literature supports the prognostic and predictive value of the values we considered.

4. Conclusions

Our results support the updated scientific literature about the BoNT-A safety profile in stroke survivors affected by spastic hemiparesis.

In our study sample, we did not observe any subclinical sign of systemic BoNT-A effects. In fact, none of our patients showed significant variations of contralateral upper limb strength and of the considered autonomic nervous system parameters from basal, even in case of high-dose treatment. Therefore, in the context of post-stroke focal spasticity treatment, we can endorse the hypothesis that BoNT-A US-guided intramuscular injections do not seem to imply systemic subclinical autonomic or muscular side effects.

Further investigations are needed in order to better clarify these findings in the general post-stroke population affected by spastic hemiparesis undergoing BoNT-A treatment. The extension of the follow-up to one month after injection may provide adjunctive data, considering the profile of the BoNT-A pharmacological effects. Future research may take into consideration a wider board of ANS parameters, hopefully with more and more accurate detection means, and multidistrict muscle strength evaluations.

5. Materials and Methods

This is a single-centered, longitudinal, observational study set in the Physical Medicine and Rehabilitation Unit of the University Hospital Maggiore della Carità-Novara (28100 Novara, Italy). We enrolled the study population among chronic stroke survivors affected by spastic hemiparesis already addressed as outpatients to our Center for the periodic clinical re-evaluation and eventual treatment with BoNT-A. No naïve patients were included in order to portray the effect of a chronic treatment.

Study participation was subordinate to the clinical indication to perform the treatment of focal spasticity with BoNT-A. The inclusion criteria were age ≥ 18 years, ischemic or hemorrhagic stroke (clinically and radiologically documented), and focal spasticity with MAS ≥ 2 affecting the upper or the lower limb. Exclusion criteria were former cardiac failure (class ≥ 3 of the New York Heart Association, NYHA [45]), previously diagnosed cardiac arrhythmia, ongoing treatment with beta-blockers, the presence of a pacemaker, and permanent contractures affecting the BoNT-A target muscles.

All the participants gave their written informed consent for study participation, structured according to the Declaration of Helsinki, and validated by the local Ethics Committee (CE registration number 160/21, Eudract number: 2019-001834-33) and the Competent Authority (Maggiore della Carità University Hospital, Novara, Italy Protocol 0016937/21, validated on 28 June 2021, amended on 1 July 2022).

Clinical evaluations were performed in two sessions: T0 (24 h before BoNT-A administration) and T1 (10 days after injection). A time lapse of 10 days was chosen according to the delayed onset of the BoNT-A pharmacological effects, typically about 10 days [46]. To perform BoNT-A inoculation, an ultrasound guide (US) was used [24,44].

BoNT-A dose was systematically assessed by the Physical Medicine and Rehabilitation Specialist based upon the severity of spasticity measured with MAS, muscle volume, and the total number of muscles treated.

The post-injection treatment protocol did not differ from the usual clinical practice, consisting in an early performed 30-min session of electrical stimulation directed to the injected muscles. During the 10 days between injection and T1, subjects underwent the usual, patient-tailored, neuromotor rehabilitation program in a day-hospital regime.

Participation in the study did not cause adjunctive costs to the patients.

In order to evaluate potential systemic and sub-clinical side effects of BoNT-A, at T0 and T1, the contralateral upper limb strength was measured through a digital dynamometer.
(DynEx1, Akern s.r.l., Florence, Italy), and ANS parameters were collected throughout a 30-min ECG registration obtained with the VU University Ambulatory Monitoring System (VU-AMS, Vrije University, Amsterdam, Netherlands) [47].

Statistical analysis relied on the Wilcoxon–Mann–Whitney rank test for non-normal distributions.

The study diagram is reported in Figure 1.

![Figure 1. Study flowchart.](image)

The handgrip strength test was conceived to determine the maximum isometric strength produced by the hand and forearm muscles. In this study, it was performed on the healthy upper limb, contralateral to the one treated with BoNT-A, according to the Southampton protocol, as described by Roberts et al. [33].

To prevent possible confounders in ECG registration, patients were asked not to smoke, not to consume caffeine or alcohol, and to avoid heavy meals and physical activity for 2 h before each measurement. Moreover, the evaluations were carried out between 11.00 a.m. and 3.00 p.m. to minimize circadian rhythm alterations.

The ECG examination was performed in a quiet room with a steady temperature of 24 °C with VU-AMS machinery equipped with surface electrodes. The registrations were then analyzed through a specific software, “VU-AMS Data, Analysis and Management Software” (VU-DAMS program, Vrije University, Amsterdam, Netherlands), version 4.0, which evaluates HRV, ICG, and RSA. Each ECG recording was analyzed, and a 20-min frame was saved.

HRV is a valuation of heart rate fluctuations, based on the measure of the R-R interval between every two consecutive heart beats, called interbeat intervals (IBIs) [35,48]. It reflects the activity and the influence of the ANS on heart function. Thus, HRV can be considered as an index of neuro-cardiac function [49].

The ICG measures the electric thoracic bioimpedance detected by surface electrodes. Largely depending on fluid thoracic content, ICG reflects the variations of thoracic blood flow. Thus, ICG is a non-invasive, cheap, and safe method to evaluate hemodynamic parameters, such as stroke volume and the PEP [36]. The surface electrodes also detect electrocardiographic signals in order to synchronize the registration of the impedance with the heart activity, obtaining a detailed ANS analysis. We used a tetrapolar impedance measurement, the most broadly employed.

RSA represents the variation of heart rate in relation to respiration. It is a physiological phenomenon, according to which, heart rate increases during inspiration and decelerates in expiration, and it is an index of vagal activity [37].

Author Contributions: Conceptualization, A.B., M.B. (Michele Bertoni), S.C. and M.I.; methodology, A.B., A.P., C.M., F.U. and A.S.; formal analysis, L.T. and M.B. (Marco Battaglia); investigation, L.T., M.B. (Marco Battaglia) and M.B.B.; resources, M.B. (Marco Battaglia), M.B.B., A.B. and A.L.; data curation, L.T., M.B. (Marco Battaglia) and M.B.B.; writing—original draft preparation, M.B. (Marco Battaglia), M.B.B. and L.T.; writing—review and editing, A.B., M.B. (Marco Battaglia) and M.B.B;
visualization, A.B., M.B. (Michele Bertoni) and M.I.; supervision, A.S., A.P., M.B. (Michele Bertoni), C.M., F.U., S.C. and L.C.; project administration, A.B., A.S., A.P., M.B. (Michele Bertoni) and L.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the local Ethics Committee (CE register number 160/21, Eudract number: 2019-001834-33) and the Competent Authority (Ospedale Maggiore della Carità University Hospital, Novara, Italy. Protocol 0016937/21, validated on 28 June 2021, amended on 1 July 2022).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patients to publish this paper.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding authors. The data are not publicly available due to the privacy protection policy.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Li, S.; Francisco, G.E.; Rymer, W.Z. A New Definition of Poststroke Spasticity and the Interference of Spasticity With Motor Recovery From Acute to Chronic Stages. *Neurorehabilit. Neural Repair* 2021, 35, 601–610. [CrossRef] [PubMed]
2. Bejot, Y.; Daubail, B.; Giroud, M. Epidemiology of stroke and transient ischemic attacks: Current knowledge and perspectives. *Rev. Neurol.* 2016, 172, 59–68. [CrossRef] [PubMed]
3. Bejot, Y.; Bailly, H.; Durier, J.; Giroud, M. Epidemiology of stroke in Europe and trends for the 21st century. *Presse Méd.* 2016, 45, e391–e398. [CrossRef] [PubMed]
4. Barthels, D.; Das, H. Current advances in ischemic stroke research and therapies. *Biochim. Biophys. Acta. Mol. Basis. Dis.* 2020, 1866, 165260. [CrossRef] [PubMed]
5. Sunnerhagen, K.S. Predictors of Spasticity After Stroke. *Curr. Phys. Med. Rehabil. Rep.* 2016, 4, 182–185. [CrossRef]
6. Schinwelski, M.J.; Sitek, E.J.; Wąz, P.; Ślawek, J.W. Prevalence and predictors of post-stroke spasticity and its impact on daily living and quality of life. *Neural. Neurochir. Pol.* 2019, 53, 449–457. [CrossRef]
7. Yew, K.S.; Cheng, E.M. Diagnosis of Acute Stroke. *Am. Fam. Physician* 2015, 91, 528–536.
8. Bushnell, C.; Bettger, J.P.; Cockcroft, K.M.; Cramer, S.C.; Edelen, M.O.; Hanley, D.; Katzan, I.L.; Mattke, S.; Nilsen, D.M.; Piquado, T.; et al. Chronic Stroke Outcome Measures for Motor Function Intervention Trials. *Circ. Cardiovasc. Qual. Outcomes* 2015, 8, S163–S169. [CrossRef] [PubMed]
9. Staub, F.; Bogousslavsky, J. Fatigue after stroke: A major but neglected issue. *Cerebrovasc. Dis.* 2001, 12, 75–81. [CrossRef]
10. Das, J.; Rajanikant, G.K. Post stroke depression: The sequelae of cerebral stroke. *Neuosci. Biobehav. Rev.* 2018, 90, 104–114. [CrossRef]
11. Glader, E.-L.; Stegmayr, B.; Asplund, K. Poststroke fatigue: A 2-year follow-up study of stroke patients in Sweden. *Stroke* 2022, 53, 1327–1333. [CrossRef] [PubMed]
12. Acciarresi, M.; Bogousslavsky, J.; Paciaroni, M. Post-Stroke Fatigue: Epidemiology, Clinical Characteristics and Treatment. *Eur. Neurol.* 2014, 72, 255–261. [CrossRef] [PubMed]
13. Dos Santos, H.M.; de Oliveira, L.C.; Bonifácio, S.R.; Brandão, T.C.P.; Silva, W.P.; Pereira, G.S.; Silva, S.M. Use of the International Classification of Functioning, Disability and Health (ICF) to expand and standardize the assessment of quality-of-life following a stroke: Proposal for the use of codes and qualifiers. *Disabil. Rehabil.* 2021, 1–6. [CrossRef] [PubMed]
14. Meseguer-Henarejos, A.B.; Sánchez-Meca, J.; López-Pina, J.A.; Carles-Hernández, R. Inter- and intra-rater reliability of the Modified Ashworth Scale: A systematic review and meta-analysis. *Eur. J. Phys. Rehabil. Med.* 2018, 54, 576–590. [CrossRef] [PubMed]
15. Harb, A.; Kishner, S. Modified Ashworth Scale. In *StatPearls*; StatPearls Publishing: Treasure Island, FL, USA, 2021. Available online: http://www.ncbi.nlm.nih.gov/books/NBK554572/ (accessed on 5 January 2022).
16. Haugh, A.B.; Pandyan, A.D.; Johnson, G.R. A systematic review of the Tardieu Scale for the measurement of spasticity. *Disabil. Rehabil.* 2006, 28, 899–907. [CrossRef] [PubMed]
17. Smania, N.; Picelli, A.; Munari, D.; Geroin, C.; Ianes, P.; Waldner, A.; Gandolfi, M. Rehabilitation procedures in the management of spasticity. *Eur. J. Phys. Rehabil. Med.* 2010, 46, 423–438.
18. He, Y.-L.; Gao, Y.; Fan, B.-Y. Effectiveness of neuromuscular electrical stimulation combined with rehabilitation training for treatment of post-stroke limb spasticity. *Medicine* 2019, 98, e17261. [CrossRef]
19. Dymarek, R.; Ptaszkowski, K.; Ptaszkowska, L.; Kowal, M.; Sopel, M.; Taradaj, J.; Rosińczuk, J. Shock Waves as a Treatment Modality for Spasticity Reduction and Recovery Improvement in Post-Stroke Adults—Current Evidence and Qualitative Systematic Review. *Clin. Interv. Aging* 2020, 15, 9–28. [CrossRef]
20. Sánchez-Mila, Z.; Salom-Moreno, J.; Fernández-de-Las-Peñas, C. Effects of dry needling on post-stroke spasticity, motor function and stability limits: A randomised clinical trial. Acupunct. Med. 2018, 36, 358–366. [CrossRef]

21. Picelli, A.; Santamato, A.; Chemello, E.; Cinone, N.; Cisari, C.; Gandolfi, M.; Ranieri, M.; Smania, N.; Baricich, A. Adjunct treatments associated with botulinum toxin injection for managing spasticity: An overview of the literature. Ann. Phys. Rehabil. Med. 2019, 62, 291–296. [CrossRef]

22. Hu, G.; Zhang, H.; Wang, Y.; Cong, D. Non-pharmacological intervention for rehabilitation of post-stroke spasticity: A protocol for systematic review and network meta-analysis. Medicine 2021, 100, e25788. [CrossRef] [PubMed]

23. Baskaran, P.; Thyagarajan, B. Acute and chronic effects of botulinum neurotoxin a on the mammalian neuromuscular junction. Muscle Nerve 2014, 40, 206–215. [CrossRef] [PubMed]

24. Wissel, J.; Ward, A.B.; Erzigaard, P.; Bensmail, D.; Hecht, M.; Lejeune, T.; Schnider, P. European consensus table on the use of botulinum toxin type A in adult spasticity. J. Rehabil. Med. 2009, 41, 13–25. [CrossRef]

25. Santamato, A.; Cinone, N.; Panza, F.; Letizia, S.; Santoro, L.; Lozupone, M.; Daniele, A.; Picelli, A.; Baricich, A.; Intiso, D.; et al. Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke. Drugs 2019, 79, 143–160. [CrossRef] [PubMed]

26. Datta Gupta, A.; Visvanathan, R.; Cameron, I.; Koblar, S.A.; Howell, S.; Wilson, D. Efficacy of botulinum toxin in modifying spasticity to improve walking and quality of life in post-stroke lower limb spasticity—A randomized double-blind placebo controlled study. BMC Neurol. 2019, 19, 96. [CrossRef] [PubMed]

27. Chang, M.A. Possible Adverse Effects of Repeated Botulinum Toxin A Injections to Decrease Post-Stroke Spasticity in Adults Undergoing Rehabilitation: A Review of the Literature. J. Allied Health 2015, 44, 140–144.

28. Padda, I.S.; Tadi, P. Botulinum Toxin. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2022. Available online: http://www.ncbi.nlm.nih.gov/books/NBK557387/ (accessed on 21 May 2022).

29. Ramirez-Castaneda, J.; Jankovic, J.; Comella, C.; Dashtipour, K.; Fernandez, H.H.; Mari, Z. Diffusion, spread, and migration of botulinum toxin. Mov. Disorder 2013, 28, 1775–1783. [CrossRef]

30. Camões-Barbosa, A.; Ribeiro, I.M.; Medeiros, L. Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity. Acta Med. Port. 2020, 33, 761–764. [CrossRef]

31. Phadke, C.P.; Balasubramanian, C.K.; Holz, A.; Davidson, C.; Ismail, F.; Boulias, C. Adverse Clinical Effects of Botulinum Toxin Intramuscular Injections for Spasticity. Can. J. Neurol. Sci. 2016, 43, 298–310. [CrossRef]

32. Jimenez-Ruiz, A.; Racosta, J.M.; Kimpinski, K.; Hilz, M.J.; Sposato, L.A. Cardiovascular autonomic dysfunction after stroke. Neurol. Sci. 2021, 42, 1751–1758. [CrossRef]

33. Roberts, H.C.; Denison, H.J.; Martin, H.J.; Patel, H.P.; Syddall, H.; Cooper, C.; Sayer, A.A. A review of the measurement of grip strength in clinical and epidemiological studies: Towards a standardised approach. Age Ageing 2011, 40, 423–429. [CrossRef]

34. Lees, T.; Shad-Kanez, F.; Simpson, A.M.; Nassif, N.T.; Lin, Y.; Lal, S. Heart Rate Variability as a Biomarker for Predicting Stroke, Post-stroke Complications and Functionality. Biomark. Insights 2018, 13, 1177271918786931. [CrossRef] [PubMed]

35. Shaffer, F.; Ginsberg, J.P. An Overview of Heart Rate Variability Metrics and Norms. Front. Public Health 2017, 5, 258. [CrossRef] [PubMed]

36. Cybulski, G.; Strasz, A.; Niewiadomska, W.; Gasiorowska, A. Impedance cardiography: Recent advancements. Cardiol. J. 2012, 19, 550–556. [CrossRef] [PubMed]

37. Yasuma, F.; Hayano, J.I. Respiratory sinus arrhythmia: Why does the heartbeat synchronize with respiratory rhythm? Chest 2004, 125, 683–690. [CrossRef] [PubMed]

38. Baricich, A.; Grana, E.; Carda, S.; Santamato, A.; Molinari, C.; Cisari, C.; Invernizzi, M. Heart Rate Variability modifications induced by high doses of incobotulinumtoxinA and onabotulinumtoxinA in hemiplegic chronic stroke patients: A single blind randomized controlled, crossover pilot study. Toxicol. 2017, 138, 145–150. [CrossRef]

39. Invernizzi, M.; Carda, S.; Molinari, C.; Stagno, D.; Cisari, C.; Baricich, A. Heart Rate Variability (HRV) modifications in adult hemiplegic patients after botulinum toxin type A (nt-201) injection. Eur. J. Phys. Rehabil. Med. 2015, 51, 353–359. [CrossRef]

40. Yaraskavitch, M.; Leonard, T.; Herzog, W. Botox produces functional weakness in non-injected muscles adjacent to the target muscle. J. Biomech. 2008, 41, 897–902. [CrossRef]

41. Yiannakopoulou, E. Serious and Long-Term Adverse Events Associated with the Therapeutic and Cosmetic Use of Botulinum Toxin. Pharmacology 2015, 95, 65–69. [CrossRef]

42. Thomas, A.M.; Simpson, D.M. Contralateral weakness following botulinum toxin for poststroke spasticity. Muscle Nerve 2012, 46, 443–448. [CrossRef]

43. Girlanda, P.; Vita, G.; Nicolosi, C.; Milone, S.; Messina, C. Botulinum toxin therapy: Distant effects on neuromuscular transmission and autonomic nervous system. J. Neurol. Neurosurg. Psychiatry 1992, 55, 844–845. [CrossRef] [PubMed]

44. Cosenza, L.; Picelli, A.; Azzolina, D.; Minetto, M.A.; Invernizzi, M.; Bertoni, M.; Santamato, A.; Baricich, A. Rectus Femoris Characteristics in Post Stroke Spasticity: Clinical Implications from Ultrasonographic Evaluation. Toxins 2020, 12, E490. [CrossRef] [PubMed]

45. Bennett, J.A.; Riegel, B.; Bittner, V.; Nichols, J. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung 2002, 31, 262–270. [CrossRef] [PubMed]

46. Sloop, R.R.; Cole, B.A.; Escutin, R.O. Human response to botulinum toxin injection: Type B compared with type A. Neurology 1997, 49, 189–194. [CrossRef] [PubMed]

47. Kunkels, Y.K.; van Roon, A.M.; Wickers, M.; Riese, H. Cross-instrument feasibility, validity, and reproducibility of wireless heart rate monitors: Novel opportunities for extended daily life monitoring. Psychophysiology 2021, 58, e13898. [CrossRef]
48. Electrophysiology TF of the ES of C the NAS of P. Heart Rate Variability. *Circulation* 1996, 93, 1043–1065. [CrossRef]
49. McCraty, R.; Shaffer, F. Heart Rate Variability: New Perspectives on Physiological Mechanisms, Assessment of Self-regulatory Capacity, and Health risk. *Glob. Adv. Health Med.* 2015, 4, 46–61. [CrossRef]